A practical guide to the management of immune thrombocytopenia co-existing with acute coronary syndrome

Department

Internal Medicine

Document Type

Article

Publication Title

Frontiers in Medicine

Abstract

Introduction: Immune thrombocytopenia (ITP) management with co-existing acute coronary syndrome (ACS) remains challenging as it requires a clinically relevant balance between the risk and outcomes of thrombosis and the risk of bleeding. However, the literature evaluating the treatment approaches in this high-risk population is scarce.

Methods and results: In this review, we aimed to summarize the available literature on the safety of ITP first- and second-line therapies to provide a practical guide on the management of ITP co-existing with ACS. We recommend holding antithrombotic therapy, including antiplatelet agents and anticoagulation, in severe thrombocytopenia with a platelet count < 30 × 109/L and using a single antiplatelet agent when the platelet count falls between 30 and 50 × 109/L. We provide a stepwise approach according to platelet count and response to initial therapy, starting with corticosteroids, with or without intravenous immunoglobulin (IVIG) with a dose limit of 35 g, followed by thrombopoietin receptor agonists (TPO-RAs) to a target platelet count of 200 × 109/L and then rituximab.

Conclusion: Our review may serve as a practical guide for clinicians in the management of ITP co-existing with ACS.

First Page

1348941

DOI

10.3389/fmed.2024.1348941

Volume

11

Publication Date

4-1-2024

PubMed ID

38665297

Link to Full Text

Share

COinS